Mechanisms of Change in Brief Treatment for Borderline Personality Disorder

Borderline Personality Disorder Clinical Trial

— BPDCHANGE  

Official title:

Mechanisms of Change in Brief Treatment for Borderline Personality Disorder: A Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03717818
• Other study ID #: 2017-02167
• Status: Recruiting
• Phase: N/A
• Start date: October 19, 2018
• Est. completion date: December 2022

Study information

• Verified date: October 2018
• Source: University of Lausanne Hospitals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present two-arm randomized controlled study aims at testing the effects (i.e., symptom reduction) and the underlying mechanisms of change associated with a brief psychiatric treatment (10 sessions over 4 months), compared with treatment as usual. Participants undergo assessments at four points (intake, 2 months, discharge and 12 month follow-up). In addition to symptom measures, all individuals undergo a two-step assessment for the potential mechanisms of change (i.e., emotion and socio-cognitive processing): a) behavioural and b) neurofunctional. We hypothesize that change in the mechanisms explains the treatment effects. The present study uses an innovative treatment of BPD and at the same time a sophisticated assessment procedure to demonstrate the critical role of psychobiological change in emotion and sociocognitive processing in brief treatments. It will help increase the effectiveness of initial treatment phase for BPD and help diminish the societal burden of disease related with BPD. This study is funded by the Swiss National Science Foundation (SNSF).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Borderline Personality Disorder

• age between 18 and 35

Exclusion Criteria:

• non-mastery in French

• neurological disorders

• schizophrenia (according to DSM-5)

Related Conditions & MeSH terms

• Borderline Personality Disorder
• Disease
• Personality Disorders

Intervention

Behavioral:
• Good Psychiatric Management - Brief
specific interventions as defined by Gunderson and Links (2014)
• treatment as usual
non-specific intervention

Locations

Country	Name	City	State
Switzerland	Department of Psychiatry-CHUV, University of Lausanne	Lausanne	VD

Sponsors (1)

Lead Sponsor	Collaborator
University of Lausanne Hospitals

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Kramer U, Kolly S, Maillard P, Pascual-Leone A, Samson AC, Schmitt R, Bernini R, Allenbach, G, Charbon P, de Roten Y, Conus P, Despland JN, Draganski B. Change in emotional processing and theory of mind processing in borderline personality disorder: A pil

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ZAN-BPD (Zanarini Borderline Personality Disorder Scale; Zanarini, 2003)	measures borderline symptomatology from an dimensional perspective, ranges between 0 and 36 (36 being the most symptomatic), global score (sum of all 9 items coded between 0 and 4) used.	4 months
Secondary	OQ-45 (Outcome Questionnaire-45.2, Lambert et al., 2004)	measures the level of problems (distress, social and interpersonal) on a scale ranging from 0 to 180 (45 items coded between 0 and 4, 4 being the most symptomatic). A total sum score will be used	4 months
Secondary	BSL-23 (Borderline Symptom List, Short Version; Bohus et al., 2009)	measures the intensity of borderline symptoms using a mean score of the 23 items ranging between 0 and 4 (4 being the most symptomatic), the mean score will be used.	4 months